Black Rock Inc. Mei Pharma, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.21 - $0.35 $40,928 - $68,214	-194,898 Reduced 12.61%	1,350,207 $310,000
Q4 2022 Feb 13, 2023	SELL	$0.22 - $8.4 $854 - $32,634	-3,885 Reduced 0.25%	1,545,105 $370,000
Q3 2022 Nov 14, 2022	SELL	$0.41 - $8.8 $3,984 - $85,527	-9,719 Reduced 0.62%	1,548,990 $599,000
Q2 2022 Aug 12, 2022	SELL	$0.42 - $0.65 $2.23 Million - $3.45 Million	-5,308,714 Reduced 77.3%	1,558,709 $943,000
Q1 2022 May 12, 2022	BUY	$0.54 - $2.74 $95,878 - $486,492	177,552 Added 2.65%	6,867,423 $4.14 Million
Q4 2021 Feb 10, 2022	BUY	$2.33 - $3.37 $195,638 - $282,962	83,965 Added 1.27%	6,689,871 $17.9 Million
Q3 2021 Nov 09, 2021	SELL	$2.52 - $2.99 $661,822 - $785,257	-262,628 Reduced 3.82%	6,605,906 $18.2 Million
Q2 2021 Aug 11, 2021	BUY	$2.6 - $3.65 $17.9 Million - $25.1 Million	6,868,534 New	6,868,534 $19.6 Million

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $366M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.